NFL is a marker of treatment response in children with SMA treated with nusinersen
Authors:
Open Access
- 23 May 2019
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 266 (9) , 2129-2136
Abstract
Background Recently, the anti-sense oligonucleotide drug nusinersen was approved for spinal muscular atrophy (SMA) and our aim was to find a response marker for this treatment. Methods Twelve children with SMA type 1 and two copies of the SMN2 gene were included in a consecutive single-center study. The children were sampled for CSF at baseline and every time nusinersen was given intrathecally. The neuronal biomarkers NFL and tau and the glial biomarker GFAP were measured. Motor function was assessed using CHOP INTEND. Eleven similarly aged children, who were investigated to rule out neurological or infectious disease, were used as controls. Results Baseline levels of NFL (4598 ± 981 vs 148 ± 39, P = 0.001), tau (939 ± 159 vs 404 ± 86, P = 0.02), and GFAP (236 ± 44 vs 108 ± 26, P = 0.02) were significantly higher in SMA children than controls. Motor function improved by nusinersen treatment in median 13 points corresponding to 5.4 points per month of treatment (P = 0.001). NFL levels typically normalized ( < 380 pg/ml) between the fourth and fifth doses [− 879.5 pg/mL/dose, 95% CI (− 1243.4, − 415.6), P = 0.0001], tau levels decreased [− 112.6 pg/mL/dose, 95% CI (− 206–7, − 18.6), P = 0.01], and minor decreases in GFAP were observed [− 16.9 pg/mL/dose, 95% CI (− 22.8, − 11.2), P = 0.02] by nusinersen treatment. Improvement in motor function correlated with reduced concentrations of NFL (rho = − 0.64, P = 0.03) and tau (rho = − 0.85, P = 0.0008) but not GFAP. Conclusions Nusinersen normalized the axonal damage marker NFL and correlated with motor improvement in children with SMA. NFL may, therefore, be a novel biomarker to monitor treatment response early in the disease course.Keywords
Funding Information
- Vetenskapsrådet (NA)
- Knut och Alice Wallenbergs Stiftelse (NA)
- Torsten Söderbergs Stiftelse (NA)
- FP7 Ideas: European Research Council (681712)
This publication has 19 references indexed in Scilit:
- CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disordersJournal of Neuroimmunology, 2014
- Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse modelNature, 2011
- Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular AtrophyScience Translational Medicine, 2011
- Amyotrophic lateral sclerosisThe Lancet, 2011
- The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): Test development and reliabilityNeuromuscular Disorders, 2010
- Cerebrospinal fluid and plasma biomarkers in Alzheimer diseaseNature Reviews Neurology, 2010
- Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSFJournal of Neurochemistry, 1996
- Identification and characterization of a spinal muscular atrophy-determining geneCell, 1995
- A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adultsJournal of Neuroscience Methods, 1994
- Localization of the glial fibrillary acidic protein in astrocytes by immunofluorescenceBrain Research, 1972